Perspectives of Individuals with Multiple Sclerosis on Discontinuation of Disease Modifying Therapies | Weatherhead School at Case Western Reserve University

Perspectives of Individuals with Multiple Sclerosis on Discontinuation of Disease Modifying Therapies

Perspectives of Individuals with Multiple Sclerosis on Discontinuation of Disease Modifying Therapies

Authors

  • Marisa P . McGinley
  • Philip Cola
  • Robert J . Fox
  • Jeffrey A . Cohen
  • John J . Corboy
  • Deborah Miller

Published

Multiple Sclerosis Journal, August 2019

Abstract

Background: Therapeutic research in multiple sclerosis (MS) has focused on the development of treatments with little investigation regarding the possibility of discontinuation of disease modifying therapies (DMTs). Objectives: To understand both the opinion of individuals with MS concerning stopping DMTs and the factors that influence the decision making process.<br>Methods: A mixed method approach was used starting with three focus groups from which a survey was developed. This survey was sent to 1,000 participants in the North American Research Committee on Multiple Sclerosis registry who met inclusion criteria (≥45 years; on most recent DMT for ≥5 years). Descriptive analysis and structural equation modeling were used.<br>Results: Of 1,000 participants receiving the survey, 377 provided complete responses and met inclusion criteria. Only 11.9% of participants reported that if their disease was considered stable, they would be very likely/likely to consider coming off medications. A high level of external locus of control in influential others such as physicians significantly decreased the likelihood of considering discontinuation.